AstraZeneca plc (AZN) Given Sell Rating at Shore Capital

AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reissued by stock analysts at Shore Capital in a research report issued on Wednesday, May 10th.

A number of other research analysts have also weighed in on the stock. Barclays PLC reissued an “overweight” rating and set a GBX 6,000 ($77.45) price target on shares of AstraZeneca plc in a research report on Monday, March 27th. Goldman Sachs Group Inc set a GBX 3,900 ($50.34) price objective on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Friday, February 3rd. Deutsche Bank AG restated a “buy” rating and set a GBX 5,500 ($71.00) price objective on shares of AstraZeneca plc in a report on Tuesday, March 21st. HSBC Holdings plc downgraded shares of AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($58.09) target price for the company. in a research note on Friday, April 7th. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 5,200 ($67.12) target price on shares of AstraZeneca plc in a research note on Tuesday, January 31st. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. AstraZeneca plc currently has an average rating of “Hold” and an average target price of GBX 5,001.80 ($64.56).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

WARNING: “AstraZeneca plc (AZN) Given Sell Rating at Shore Capital” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

12 Month Chart for LON:AZN

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply